- Home
- PHAR vs CAC Comparison
PHAR vs CAC Comparison
Compare PHAR & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | CAC |
|---|---|---|
| Founded | 1988 | 1875 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 680.5M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | PHAR | CAC |
|---|---|---|
| Price | $17.29 | $45.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $30.00 | ★ $47.33 |
| AVG Volume (30 Days) | 19.3K | ★ 71.2K |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | N/A | ★ 3.76% |
| EPS Growth | N/A | ★ 9.13 |
| EPS | 0.00 | ★ 3.49 |
| Revenue | ★ $362,274,000.00 | $215,172,000.00 |
| Revenue This Year | $24.80 | $44.50 |
| Revenue Next Year | $6.84 | $7.03 |
| P/E Ratio | $3,117.90 | ★ $12.80 |
| Revenue Growth | 26.78 | ★ 27.50 |
| 52 Week Low | $7.50 | $34.53 |
| 52 Week High | $17.86 | $47.55 |
Technical Indicators
Market Signals| Indicator | PHAR | CAC |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 74.91 |
| Support Level | $15.76 | $41.38 |
| Resistance Level | $17.35 | $41.60 |
| Average True Range (ATR) | 0.73 | 1.21 |
| MACD | -0.01 | 0.37 |
| Stochastic Oscillator | 86.19 | 95.55 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.